Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30:13:906328.
doi: 10.3389/fimmu.2022.906328. eCollection 2022.

Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling

Affiliations
Review

Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling

Sara Bohnstedt Mørup et al. Front Immunol. .

Abstract

Background: Knowledge of the genetic variation underlying Primary Immune Deficiency (PID) is increasing. Reanalysis of genome-wide sequencing data from undiagnosed patients with suspected PID may improve the diagnostic rate.

Methods: We included patients monitored at the Department of Infectious Diseases or the Child and Adolescent Department, Rigshospitalet, Denmark, for a suspected PID, who had been analysed previously using a targeted PID gene panel (457 PID-related genes) on whole exome- (WES) or whole genome sequencing (WGS) data. A literature review was performed to extend the PID gene panel used for reanalysis of single nucleotide variation (SNV) and small indels. Structural variant (SV) calling was added on WGS data.

Results: Genetic data from 94 patients (86 adults) including 36 WES and 58 WGS was reanalysed a median of 23 months after the initial analysis. The extended gene panel included 208 additional PID-related genes. Genetic reanalysis led to a small increase in the proportion of patients with new suspicious PID related variants of uncertain significance (VUS). The proportion of patients with a causal genetic diagnosis was constant. In total, five patients (5%, including three WES and two WGS) had a new suspicious PID VUS identified due to reanalysis. Among these, two patients had a variant added due to the expansion of the PID gene panel, and three patients had a variant reclassified to a VUS in a gene included in the initial PID gene panel. The total proportion of patients with PID related VUS, likely pathogenic, and pathogenic variants increased from 43 (46%) to 47 (50%), as one patient had a VUS detected in both initial- and reanalysis. In addition, we detected new suspicious SNVs and SVs of uncertain significance in PID candidate genes with unknown inheritance and/or as heterozygous variants in genes with autosomal recessive inheritance in 8 patients.

Conclusion: These data indicate a possible diagnostic gain of reassessing WES/WGS data from patients with suspected PID. Reasons for the possible gain included improved knowledge of genotype-phenotype correlation, expanding the gene panel, and adding SV analyses. Future studies of genotype-phenotype correlations may provide additional knowledge on the impact of the new suspicious VUSs.

Keywords: gene panel analysis; primary immune deficiencies (PID); reanalysis approach; single nucleotide variant analysis; small INDELs; structural variation analysis; whole exome sequencing; whole genome sequencing (WGS).

PubMed Disclaimer

Conflict of interest statement

TK has participated in advisory boards for Gilead Sciences, GlaxoSmithKline/ViiV and MSD. TK has received fees for teaching from Takeda and CSL Behring, and a research grant from Gilead Sciences. MH has participated in advisory boards for AstraZeneca, Gilead Sciences, GlaxoSmithKline/ViiV, MSD, Roche, and Sobi. MH has received fees for teaching from Gilead Sciences and GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of patient inclusion.
Figure 2
Figure 2
Distribution of the genetic results (PID-1 and PID-2 combined) across ESID (2019) subgroups (n = 95 patients). *The Familial Chronic Mucocutanous Candidiasis subgroup includes the one patient excluded from reanalysis. †One child with CVID was included, as the child is part of a family including a parent and sibling with antibody deficiency. ‡Includes eight patients with suspicious PID variants (LP/P) and 28 patients with suspicious PID variants (VUS), of which one is included in the five patients with new suspicious VUS(s) detected due to reanalysis, since this patient also had a suspicious PID VUS detected in the reanalysis. VUS, variant of uncertain significance; LP, likely pathogenic; P, pathogenic.

Similar articles

Cited by

References

    1. Mahlaoui N, Warnatz K, Jones A, Workman S, Cant A. Advances in the Care of Primary Immunodeficiencies (PIDs): From Birth to Adulthood. J Clin Immunol (2017) 37:452–60. doi: 10.1007/s10875-017-0401-y - DOI - PMC - PubMed
    1. Zhang Q, Frange P, Blanche S, Casanova JL. Pathogenesis of Infections in HIV-Infected Individuals: Insights From Primary Immunodeficiencies. Curr Opin Immunol (2017) 48:122–33. doi: 10.1016/j.coi.2017.09.002 - DOI - PMC - PubMed
    1. Denning L. Primary Immunodeficiencies for General Practitioners – Making a Difference in Diagnosing Severe Illness. J Fam Med Prim Care (2017) 6:709. doi: 10.4103/jfmpc.jfmpc_414_16 - DOI - PMC - PubMed
    1. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee. J Clin Immunol (2020) 40:24–64. doi: 10.1007/s10875-019-00737-x - DOI - PMC - PubMed
    1. Yska HAF, Elsink K, Kuijpers TW, Frederix GWJ, van Gijn ME, van Montfrans JM. Diagnostic Yield of Next Generation Sequencing in Genetically Undiagnosed Patients With Primary Immunodeficiencies: A Systematic Review. J Clin Immunol (2019) 39:577–91. doi: 10.1007/s10875-019-00656-x - DOI - PMC - PubMed

Publication types

LinkOut - more resources